Search

Author/Creator Strand, V

1. 059 A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis. (12th April 2019)

Authors:
van Vollenhoven, R; Takeuchi, T; Pangan, A L; Friedman, A; Mohamed, M F; Chen, S; Rischmueller, M; Blanco, R; Xavier, R M; Strand, V
Journal:
Rheumatology
Issue:
Volume 58(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Issue 6 (29th November 2007)

Authors:
Taylor, W J; Schumacher, H R; Baraf, H S B; Chapman, P; Stamp, L; Doherty, M; McQueen, F; Dalbeth, N; Schlesinger, N; Furst, D E; Mellado, J Vazquez; Becker, M A; Kavanaugh, A; Louthrenoo, W; Bardin, T; Khanna, D; Simon, L S; Yamanaka, H; Choi, H K; Zeng, X
Journal:
Annals of the rheumatic diseases
Issue:
Volume 67:Issue 6(2008)
Page Start:
888
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Issue 7 (10th February 2012)

Authors:
Mease, P; Strand, V; Shalamberidze, L; Dimic, A; Raskina, T; Xu, Li-An; Liu, Y; Smith, J
Journal:
Annals of the rheumatic diseases
Issue:
Volume 71:Issue 7(2012)
Page Start:
1183
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. AB0685 Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with ankylosing spondylitis: long-term results from measure 1 and measure 2. (15th June 2017)

Authors:
Deodhar, A; Conaghan, PG; Strand, V; Boonen, A; Ferraccioli, G; Bosch, F Van den; Bhosekar, V; Porter, B; Gandhi, K; Jugl, S
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
1293
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. AB0765 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved disease activity index for psoriatic arthritis (DAPSA) remission. (15th June 2017)

Authors:
Smolen, JS; McInnes, IB; Gossec, L; Strand, V; Pricop, L; Fox, T; Jugl, S; Gaillez, C
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
1322
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS). (15th June 2017)

Authors:
Coates, LC; Kvien, TK; Nash, P; Gossec, L; Strand, V; Pricop, L; Rasouliyan, L; Ding, K; Jugl, S; Gaillez, C
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
1326
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. AB0786 Systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a grappa-omeract initiative. (15th June 2017)

Authors:
Højgaard, P; Klokker, L; Orbai, A-M; Holmsted, K; Bartels, EM; Leung, YY; Goel, N; Wit, M de; Gladman, D; Mease, P; Dreyer, L; Kristensen, LE; FitzGerald, O; Tillett, W; Gossec, L; Helliwell, P; Strand, V; Ogdie, A; Terwee, C; Christensen, R
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
1332
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗